Hospital
Peacehealth
Peacehealth was paid $34.33M by Medicaid between Jan 2018 and Dec 2024, across 188 billing codes. Its largest line is 99285, emergency room visit (most serious) — 15% of everything it billed.
33Billing provider infoPEACEHEALTH
KETCHIKAN, AK 99901
KETCHIKAN, AK 99901
33aNPI1396705539assigned 03/23/2006
33bProvider typeCritical Access Hospital
28Total paid$34.33M
24GClaims331,294
24DCodes billed188
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Alaska
Rank by total paid#4 of 8
Median peer was paid$17.70M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 54,294 | $5.44M | |
| 2019 | 50,181 | $5.69M | |
| 2020 | 43,482 | $4.66M | |
| 2021 | 48,896 | $4.55M | |
| 2022 | 48,960 | $4.99M | |
| 2023 | 45,409 | $4.70M | |
| 2024incomplete | 40,072 | $4.29M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 7,960 | 6,737 | $5.27M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9.3% | 2,592 | 2,061 | $3.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.0% | 7,398 | 6,287 | $3.08M |
| 41899 | Unlisted procedure, dentoalveolar structures | 7.0% | 717 | 683 | $2.41M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.6% | 7,682 | 6,791 | $1.92M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 2,694 | 2,055 | $1.53M |
| G0378 | Hospital observation service, per hour | 3.5% | 1,391 | 1,130 | $1.19M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 11,625 | 3,686 | $950K |
| 80053 | Comprehensive metabolic panel | 2.4% | 17,411 | 13,988 | $811K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.3% | 4,782 | 3,729 | $776K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 4,510 | 3,859 | $732K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 4,250 | 3,188 | $719K |
176 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 20,628 | $537K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 5,300 | $429K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 5,887 | $429K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.2% | 561 | $414K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 3,193 | $371K |
| 84484 | 1.1% | 5,895 | $370K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,167 | $319K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 425 | $298K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,650 | $294K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,316 | $283K |
| 87631 | <1% | 1,915 | $278K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,209 | $266K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,408 | $263K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,467 | $260K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,797 | $230K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,943 | $214K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 14,569 | $208K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,930 | $180K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,049 | $175K |
| 83605 | <1% | 3,406 | $163K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,567 | $159K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 60 | $156K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 204 | $154K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,988 | $154K |
| 84703 | <1% | 3,490 | $153K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,796 | $150K |
| 83735 | <1% | 5,443 | $150K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,306 | $142K |
| 83880 | <1% | 1,502 | $141K | |
| 81001 | <1% | 7,673 | $140K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,447 | $136K |
| 86850 | <1% | 1,246 | $131K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,818 | $131K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 677 | $128K |
| 83690 | <1% | 4,105 | $128K | |
| 80061 | Lipid panel | <1% | 3,090 | $121K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 362 | $115K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,704 | $111K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 703 | $108K |
| 73562 | <1% | 709 | $105K | |
| 96376 | <1% | 2,034 | $103K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,445 | $100K |
| 80305 | <1% | 2,357 | $99K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 377 | $96K |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,915 | $91K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,616 | $89K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,482 | $89K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,413 | $89K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,003 | $82K |
| 85379 | <1% | 890 | $78K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,426 | $77K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 212 | $77K |
| 97161 | <1% | 611 | $70K | |
| 76830 | Ultrasound, transvaginal | <1% | 350 | $68K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,608 | $68K |
| 86140 | <1% | 2,698 | $67K | |
| 84439 | <1% | 1,841 | $66K | |
| 87081 | <1% | 1,731 | $64K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 782 | $62K |
| 87186 | <1% | 1,520 | $61K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,856 | $59K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 574 | $59K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,669 | $58K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 461 | $57K |
| 73630 | <1% | 382 | $55K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 6,521 | $55K |
| 73030 | <1% | 526 | $54K | |
| 96367 | <1% | 529 | $53K | |
| 86803 | <1% | 1,009 | $53K | |
| 73610 | <1% | 389 | $51K | |
| 87040 | <1% | 985 | $47K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,930 | $47K |
| 85610 | <1% | 2,712 | $38K | |
| 85027 | <1% | 1,712 | $37K | |
| 86901 | <1% | 1,403 | $36K | |
| 86900 | <1% | 1,391 | $36K | |
| 85730 | <1% | 1,250 | $31K | |
| 85652 | <1% | 2,178 | $30K | |
| 97162 | <1% | 226 | $29K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 796 | $28K |
| 82728 | <1% | 761 | $27K | |
| 73130 | <1% | 176 | $26K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 535 | $24K |
| 82570 | <1% | 900 | $23K | |
| 87430 | <1% | 677 | $22K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,536 | $21K |
| 82043 | <1% | 385 | $20K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,022 | $18K |
| 82607 | <1% | 264 | $18K | |
| 83550 | <1% | 446 | $17K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 584 | $17K |
| 83540 | <1% | 495 | $15K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 14 | $14K |
| 86780 | <1% | 236 | $12K | |
| 81003 | <1% | 821 | $12K | |
| 82803 | <1% | 292 | $12K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 403 | $11K |
| 73110 | <1% | 64 | $11K | |
| 71250 | <1% | 17 | $11K | |
| 73502 | <1% | 83 | $10K | |
| 87205 | <1% | 436 | $10K | |
| 87070 | <1% | 217 | $9K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 30 | $9K |
| 96368 | <1% | 113 | $9K | |
| 72100 | <1% | 58 | $9K | |
| 87147 | <1% | 247 | $9K | |
| 87077 | <1% | 216 | $8K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 15 | $8K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 297 | $7K |
| 86696 | <1% | 80 | $7K | |
| 80306 | <1% | 453 | $7K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 17 | $6K |
| 94060 | <1% | 16 | $6K | |
| 82746 | <1% | 116 | $6K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $5K |
| 87340 | <1% | 149 | $5K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 54 | $5K |
| 84702 | <1% | 49 | $4K | |
| 86695 | <1% | 67 | $4K | |
| 81025 | <1% | 115 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 13 | $4K |
| 90715 | <1% | 102 | $4K | |
| 84100 | <1% | 156 | $4K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 118 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 100 | $3K |
| 82550 | <1% | 121 | $3K | |
| 82150 | <1% | 74 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 129 | $3K |
| 87808 | <1% | 61 | $3K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 31 | $2K |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 41 | $2K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 20 | $2K |
| 87210 | <1% | 80 | $2K | |
| 84460 | <1% | 116 | $2K | |
| 84450 | <1% | 115 | $2K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 382 | $2K |
| 94729 | <1% | 16 | $2K | |
| 85007 | <1% | 99 | $2K | |
| 71271 | <1% | 12 | $1K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 148 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 50 | $1K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 98 | $1K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 53 | $1K |
| 97116 | <1% | 22 | $1K | |
| 80076 | <1% | 45 | $998.33 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 207 | $953.63 |
| 20610 | <1% | 45 | $835.37 | |
| 86038 | <1% | 19 | $808.94 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 665 | $786.97 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 33 | $745.09 |
| 99442 | <1% | 90 | $733.37 | |
| 84550 | <1% | 32 | $621.56 | |
| 82553 | <1% | 13 | $596.76 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $559.25 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 165 | $545.54 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 17 | $533.30 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 20 | $469.39 |
| 87581 | <1% | 13 | $430.21 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 17 | $397.11 |
| 86431 | <1% | 15 | $389.25 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 189 | $371.84 |
| 82272 | <1% | 42 | $344.23 | |
| 82950 | <1% | 12 | $260.60 | |
| 90686 | <1% | 84 | $128.04 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 90 | $76.45 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 34 | $76.41 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 67 | $72.61 |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 14 | $68.94 |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 20 | $52.65 |
| 93793 | <1% | 29 | $33.82 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 40 | $23.27 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 16 | $0.01 |
| A9270 | Non-covered item or service | 0% | 3,803 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 194 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 13 | $0.00 |
| 80346 | 0% | 186 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRANCO, PATRICK (CEO)
| Provider | Location | Paid |
|---|---|---|
| Peacehealth | Ketchikan, AK | $2.92M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.